St. Jude Reference #SJ-20-0028
Current AD diagnosis is largely based on expensive brain imaging tests like PET, memory tests, and CSF assays. No AD blood test is available so far. Due to the limitations of the high cost and insufficient accessibility of PET, and the limited accessibility and invasive nature of CSF collection, the identification of AD-correlated proteins in blood/plasma/serum has greater potential to develop first-line diagnostic tools for AD.
Researchers at St. Jude developed new methods of diagnosing Alzheimer’s disease (AD) by analyzing patient proteins and/or protein expression profiles. They believe their methods can be used to affordably diagnosis preclinical or symptomatic stages of Alzheimer's disease, and mild cognitive impairment by quantification of a subset of novel proteins in blood/plasma/serum in individuals, as well as evaluating the progression of AD progression in patients, and for analyzing the outcome of potential AD therapies.
Blood Biomarker, Alzheimer's Disease, diagnosis, proteins, therapy
Granted patents or published applications
International application published as WO 2021/234607
Related scientific references
Wang et al., “Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease.” Molecular Neurodegeneration (2020) https://doi.org/10.1186/s13024-020-00384-6
Dey et al., “Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer’s diseaseClin Proteom (2019) https://doi.org/10.1186/s12014-019-9237-1
Please contact us if you are interested in licensing this technology. Contact: firstname.lastname@example.org
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.